Teva Pharmaceutical Industries PE Ratio 2012-2026 | TEVA
Current and historical p/e ratio for Teva Pharmaceutical Industries (TEVA) from 2012 to 2026. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Teva Pharmaceutical Industries PE ratio as of September 16, 2026 is 17.67.
| Teva Pharmaceutical Industries PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-09-17 | 39.19 | 64.25 | |
| 2026-06-30 | 33.88 | $0.61 | 55.54 |
| 2026-03-31 | 30.12 | $1.34 | 22.48 |
| 2025-12-31 | 31.21 | $1.21 | 25.79 |
| 2025-09-30 | 20.20 | $0.60 | 33.67 |
| 2025-06-30 | 16.76 | $-0.16 | 0.00 |
| 2025-03-31 | 15.37 | $-1.15 | 0.00 |
| 2024-12-31 | 22.04 | $-1.45 | 0.00 |
| 2024-09-30 | 18.02 | $-0.84 | 0.00 |
| 2024-06-30 | 16.25 | $-0.39 | 0.00 |
| 2024-03-31 | 14.11 | $-0.42 | 0.00 |
| 2023-12-31 | 10.44 | $-0.50 | 0.00 |
| 2023-09-30 | 10.20 | $-2.10 | 0.00 |
| 2023-06-30 | 7.53 | $-2.11 | 0.00 |
| 2023-03-31 | 8.85 | $-1.54 | 0.00 |
| 2022-12-31 | 9.12 | $-2.20 | 0.00 |
| 2022-09-30 | 8.07 | $-1.16 | 0.00 |
| 2022-06-30 | 7.52 | $-0.95 | 0.00 |
| 2022-03-31 | 9.39 | $-0.55 | 0.00 |
| 2021-12-31 | 8.01 | $0.38 | 21.08 |
| 2021-09-30 | 9.74 | $0.66 | 14.76 |
| 2021-06-30 | 9.90 | $-3.57 | 0.00 |
| 2021-03-31 | 11.54 | $-3.63 | 0.00 |
| 2020-12-31 | 9.65 | $-3.64 | 0.00 |
| 2020-09-30 | 9.01 | $-3.67 | 0.00 |
| 2020-06-30 | 12.33 | $0.01 | 1233.00 |
| 2020-03-31 | 8.98 | $-0.75 | 0.00 |
| 2019-12-31 | 9.80 | $-0.91 | 0.00 |
| 2019-09-30 | 6.88 | $-3.89 | 0.00 |
| 2019-06-30 | 9.23 | $-3.87 | 0.00 |
| 2019-03-31 | 15.68 | $-3.48 | 0.00 |
| 2018-12-31 | 15.42 | $-2.35 | 0.00 |
| 2018-09-30 | 21.54 | $-10.89 | 0.00 |
| 2018-06-30 | 24.32 | $-10.10 | 0.00 |
| 2018-03-31 | 17.09 | $-15.80 | 0.00 |
| 2017-12-31 | 18.95 | $-16.26 | 0.00 |
| 2017-09-30 | 17.49 | $-5.95 | 0.00 |
| 2017-06-30 | 32.84 | $-6.12 | 0.00 |
| 2017-03-31 | 31.34 | $0.02 | 1566.90 |
| 2016-12-31 | 35.06 | $0.07 | 500.91 |
| 2016-09-30 | 44.10 | $1.72 | 25.64 |
| 2016-06-30 | 47.84 | $1.49 | 32.11 |
| 2016-03-31 | 50.63 | $1.92 | 26.37 |
| 2015-12-31 | 61.73 | $1.82 | 33.92 |
| 2015-09-30 | 52.79 | $2.07 | 25.50 |
| 2015-06-30 | 54.99 | $2.97 | 18.51 |
| 2015-03-31 | 57.64 | $3.21 | 17.96 |
| 2014-12-31 | 52.89 | $3.56 | 14.86 |
| 2014-09-30 | 49.16 | $3.20 | 15.36 |
| 2014-06-30 | 47.62 | $3.02 | 15.77 |
| 2014-03-31 | 47.67 | $1.62 | 29.43 |
| 2013-12-31 | 35.89 | $1.49 | 24.09 |
| 2013-09-30 | 33.55 | $1.43 | 23.46 |
| 2013-06-30 | 34.53 | $0.50 | 69.06 |
| 2013-03-31 | 34.67 | $2.02 | 17.16 |
| 2012-12-31 | 32.36 | $2.25 | 14.38 |
| 2012-09-30 | 35.65 | $2.45 | 14.55 |
| 2012-06-30 | 33.75 | $3.57 | 9.45 |
| 2012-03-31 | 38.30 | $3.22 | 11.90 |
| 2011-12-31 | 34.10 | $3.09 | 11.04 |
| 2011-09-30 | 31.28 | $3.36 | 9.31 |
| 2011-06-30 | 40.30 | $3.48 | 11.58 |
| 2011-03-31 | 41.74 | $3.72 | 11.22 |
| 2010-12-31 | 43.18 | $3.67 | 11.77 |
| 2010-09-30 | 43.53 | $3.24 | 13.44 |
| 2010-06-30 | 42.74 | $2.81 | 15.21 |
| 2010-03-31 | 51.69 | $2.51 | 20.59 |
| 2009-12-31 | 45.89 | $2.23 | 20.58 |
| 2009-09-30 | 41.17 | $0.93 | 44.27 |
| 2009-06-30 | 40.06 | $0.98 | 40.88 |
| 2009-03-31 | 36.46 | $1.05 | 34.72 |
| 2008-12-31 | 34.34 | $0.72 | 47.70 |
| 2008-09-30 | 36.84 | $2.29 | 16.09 |
| 2008-06-30 | 36.75 | $2.16 | 17.01 |
| 2008-03-31 | 36.95 | $2.14 | 17.27 |
| 2007-12-31 | 37.09 | $2.38 | 15.58 |
| 2007-09-30 | 35.40 | $2.24 | 15.80 |
| 2007-06-30 | 32.77 | $2.34 | 14.00 |
| 2007-03-31 | 29.66 | $2.30 | 12.89 |
| 2006-12-31 | 24.56 | $0.48 | 51.17 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $44.899B | $17.258B |
| Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |